---



SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM 10-KSB



|x | ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ------------------------------------------------------------------------------



For the Fiscal Year Ended December 31, 2004



| ̈ | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------



For the transition period from
 to



Commission file number: 001-13467



COMMONWEALTH BIOTECHNOLOGIES, INC.

(Name of small business issuer in its charter)



|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Virginia                                                       |  | 54-1641133                          
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)



601 Biotech Drive

Richmond, Virginia 23235

(Address of principal executive offices) (Zip Code)



Issuers telephone number: (804) 648-3820



|                                                                 |  |                                                            
|---------------------------------------------------------------- |  | -----------------------------------------------------------
|Securities registered pursuant to Section 12(b) of the Act:      |  | Securities registered pursuant to Section 12(g) of the Act:
|Common Stock, without par value per share NASDAQ SmallCap Market |  | None                                                       



Check whether the
issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes x No ̈



Check if there is no disclosure of delinquent filers in response to Item 405
of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to
this Form 10-KSB ̈.



The issuers revenues for the year ended December 31, 2004 were $ 5,748,704.



The aggregate market value of the shares of common stock, without par value (Common Stock), of the registrant
held by non-affiliates on March 21, 2005 was approximately $1,181,991 based on the closing sales price of the shares of $ 4.22 per share, as reported on the NASDAQ Market on March 21, 2005.



As of March 21, 2005, there were 3,203,556 shares of Common Stock
outstanding.



DOCUMENTS INCORPORATED BY REFERENCE



Portions of the registrants definitive proxy
statement for its Annual Meeting of Shareholders to be held on May 20, 2005 are incorporated by reference into Part III of this Form 10-KSB.



Portions of the registrants 2004 Annual Report to Shareholders are incorporated by reference into Part II of this Form 10-KSB.



Transitional Small Business Disclosure Format (check one:) Yes ̈No x.



---



---

PART I



|Item 1. | Description of Business.
|------- | ------------------------



Overview



Commonwealth Biotechnologies, Inc. (the Company or CBI) was founded in 1992 to provide sophisticated research and development support services in the life sciences on a contract basis to
private companies, academic institutions and government agencies. In each of these areas, the Company provides sophisticated macromolecular synthetic and analytical services, integrating individual platform technologies so as to provide a
comprehensive approach to solving complex problems in life science research.



The Company provides these services to customers on a contract basis and derives its revenues from these services, and not only from sales of commercial products resulting from the research. This arrangement distinguishes the Company from
many other biotechnology companies in that the Companys revenues are not derived from successful commercialization of a new biotechnology product. The Company has developed a strong reputation as a leading provider of biotechnology research
and development analytical services and in particular, has positioned itself as a leading provider of fundamental programs as they relate to bio-defense. The Company is focusing its expansion efforts on increasing its long-term relationships with
customers in the private sector biotechnology companies, in major pharmaceutical companies, and in comprehensive government programs. The Company continues to keep pace with new technologies and is able to offer these new services to its customers.
In particular, the Company is focused on providing its technology offerings under strict Good Laboratory Practices GLP guidelines, which makes the Company very attractive to those entities, which require assurance that the work done is
of the highest quality possible.



The Companys approach to providing
services is called Concept-to-Clinic and is the key to CBIs continued success. It defines the approach taken with all clients  design, development, implementation and testing. Whether the client is a start-up company with
research and development needs, or an established firm wishing to move a product through clinical regulation, CBI stands ready as partner of choice to provide the required services that ensures success. The use of Concept-to-Clinic is evidenced in
the broad array of services CBI offers its clients.



Growth Strategy



On December 16, 2004, the Company purchased the assets of Fairfax
Identity Labs, FIL, a division of Genetics and In-Vitro Fertilization Institute and their operations were moved to the corporate office in Richmond, VA. The principal focus of the purchase was to increase the revenue base of private
paternity, contract paternity testing, and forensic DNA analysis. There has been a significant increase in the number of private paternity cases implemented at the Company and in the number of molecular diagnostic assays performed.



The Company is vigorously pursuing revenue opportunities in four principal focus areas:
bio-defense; laboratory support services for on-going clinical trials; comprehensive contract projects in the private sector; paternity testing, forensic case-work analysis and CODIS (Combined DNA Index System) work through its FIL division.
While the majority of the Companys customers are in the private sector, the bulk of the Companys revenues (about 71%) in 2004 were derived from government contracts, and in particular, from government contracts dealing with bio-defense
related matters. Results derived by the Company are used by others to support their own compliance filings, to further their own in-house research efforts, to implement new assay technologies, and the like.



2



---

In all its core focus areas, the Company is continuing to grow its contract base. With regard to government contracts,
the Company acts as both prime and subcontractor to numerous federal agencies. More often than not, the Company is the prime (if not the only) contractor performing clinical laboratory or comprehensive contracts for its private sector clients. The
Company is moving towards equalizing revenues from the private sector and the government sector. To this end, the Company formed an exclusive alliance with Fisher Scientific, LLC, Pittsburgh, PA with the principle objective of using the Fisher sales
force to promote CBIs platform technologies with private sector companies. The Fisher/CBI alliance was officially launched in October, 2004.



The Company also derives revenues from genetic identity and clinical services. The Company designed and implemented molecular diagnostic assays for the presence of DNA
attributable to the various human herpes viruses. This platform technology is being used to serve individual patients across the country and in support of an on-going clinical study with a new anti-viral therapeutic. The Company has grown its
molecular diagnostic platform in several other critical areas and its services are being used in support of still other on-going clinical trials and in support of fundamental research and development programs for its clients.



The Companys customers provide repeat business to the Company. The Company views
commercial and government contracts as its most important sources of revenue and for this reason, has moved away from concept of piece work for individual investigators. With all its contracts, revenues are generally recognized as
services are rendered or as products are delivered. In some instances, revenue is also recognized with performance-based installments payable over the contract as milestones are achieved.



Other areas for the Companys growth include:



| |  |  | Laboratory Services in Support of Vaccine Development. The Company believes that there is a continuing need for GLP rated facilities to perform validated assay work on
experimental vaccines targeting select agent pathogens. CBI is currently performing such work under long-term contracts to different industry clients and has expanded its technical and compliance capabilities in this area.
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Microbiology. Working individually or teamed with industry partners, CBI offers traditional and cutting edge microbiological analyses. Current clients include those looking
to confirm the presence of suspected pathogens in suspicious powders. CBI also is consulting with major food providers to put in place rapid and meaningful assays and surveys for food borne pathogens.
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | Genomics/Proteomics. As the DNA make-up of individual organisms (including humans) is unveiled, CBI is able to help identify and characterize the proteins that make up the
proteome encoded by the DNA. The Company believes that its genomics and proteomics capabilities are well recognized and has received to contracts from non-profit private organizations IITRI and from the National
Institutes of Health in pursuit of these kinds of studies. CBI specializes at developing novel mass spectral methods for characterization of organismal proteomes.
| | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| |  |  | DNA Reference Lab Activities. Through its FIL division, CBI has greatly expanded and enhanced its capabilities in this area, where chain-of-custody and accurate analyses are
absolute requisites. In addition to paternity testing, CBI offers analysis of forensic samples, Y-chromosome STR analysis, to help clearly distinguish the male contributor in a mixed DNA sample, genetic and CODIS (Combined DNA Index System)
analyses, mitochondrial DNA sequence analysis, to help identify a suspect individual by direct comparison with a maternally related individual, specimen matching and ID Personal DNA Profiling. In this last technology area, termed CID for
Confidential Identity, a client is provided with a DNA profile sufficient to serve as the basis of identification in case of tragedy.
| | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



3



---

Regulatory Compliance



The Company is registered under the Clinical Laboratories Improvement Act CLIA that enables the Company to accept human samples for analysis and to perform
analysis of human clinical samples for the presence of known genetic markers.



The Company is also accredited under the guidelines of the National Forensic Science Technology Center, NFSTC, to perform DNA identity testing for submission of data into the CODIS data base, and is one of a select few
commercial facilities nationwide accredited by the NFSTC to perform criminal (felony) DNA database testing for submission into the FBI CODIS database.



The American Association of Blood Banks AABB accredits the Company, and the Company has participated in a validation study through the College of American
Pathologists CAP. Accreditation by the AABB enables the Company to perform paternity testing on private and public cases.



The Company is also accredited by the Centers for Disease Control to receive and handle select agents. The Company operates and maintains an accredited Biosafety level 3
facility which houses bacteriology and virology laboratories.



The Company
operates under strict Good Laboratory Practices GLP guidelines and has been successfully audited by a number of private companies and governmental agencies.



Analytical Support Services



The Company is a fee-for-service contractor offering integrated programs that span the gamut of state-of-the-art life sciences investigations. Typically, the Company
takes no ownership position in the intellectual property rights resulting from services it performs under contract for its customers. Since commencing operations, the Company has become noted for providing a wide range of services relating to
design, synthesis, purification, and analysis of peptides, proteins, and oligonucleotides and in creating unique assay and detection methods.



CBIs competitive edge resides in its ability to provide a wide range of services in fully integrated research programs. There are few major competitors, which offer
integrated DNA/RNA and protein/peptide technologies and none that offer these technologies combined with sophisticated biophysical analytical techniques, such as calorimetry, spectroscopy, and mass spectral analysis. Thus, the Company can provide
complete research programs to its customers. One stop biotechnology shopping has proved attractive in securing long-term contracts with customers ranging from major pharmaceutical industry researchers to major government sponsors of
research, including agencies of the Department of Defense.



The services
offered by the Company are fully detailed in its promotional brochures, and on its World Wide Web page. The Company offers fax-on-demand for customers who seek technology descriptions and pricing information.



Customers



CBI re-defined its client base to focus on long-term project goals, rather than on individual orders for selected technologies. CBIs
clients are from private companies, academic institutions and government agencies across the globe. Whether the client is a start-up company with research and development needs, or an established firm wishing to move a product through the regulatory
process, CBI stands ready as partner of choice to provide the required services that ensure success.



4



---

Over the years, CBI has re-priced its platform technologies to maintain its margins while maintaining its competitive
edge. In several instances, CBI ceased to offer a technology service when it became clear that the price needed to pay its overhead and maintain its margin made CBI non-competitive in the market place. CBI management continuously reviews its pricing
policies.



Proprietary Research and Development



CBI has developed its own intellectual properties that could potentially add a significant
revenue stream to the Company when they are fully commercialized. However, CBI is focused entirely on its core competencies and as such, has more or less abandoned development of intellectual properties. CBIs focus with regard to its patent
portfolio is to find third party licensees who can fully exploit a products potential.



The Company takes appropriate steps to protect its intellectual property rights and those of its customers. The Companys practice is to require its employees and consultants to execute non-disclosure and
proprietary rights agreements upon commencement of employment or consulting arrangements with the Company. These agreements acknowledge the Companys exclusive ownership of all intellectual property developed by the individual during the course
of his work with the Company and require that all proprietary information disclosed to the individual by the Company or its customers remain confidential.



Marketing



The Company has expanded its customer base primarily through word-of-mouth referrals, attendance at a limited number of trade shows, seminars, and on-site meetings with decision makers. Because of its ability to offer
a wide range of biotechnology research services, the Company enjoys a favorable reputation among its customers, and many new customers come to the Company by word-of-mouth recommendation. The Company has constructed its own World Wide Web Home Page
(www.cbi-biotech.com) and is listed with several bio-technical and biomedical oriented sites on the World Wide Web.



The Company has developed a marketing plan which addresses several key issues, including;



| |  |  | New webbased initiatives:
| | - |  | --------------------------



The CBI web page is being re-designed to make it more user friendly and easier to navigate. New web sites will promote the forensics capabilities at CBI,
and the herpes virus testing platform web page will be upgraded. CBIs web site prominence will be enhanced through search engine optimization, and finally, the Company is planning on providing periodic, information-based newsletters.



| |  |  | A refocus of the Companys media efforts:
| | - |  | -----------------------------------------



The Company will update and re-vamp its technical brochures, promotional pieces, and trade show booth presentations. Individual sales flyers will be
distributed which detail the specific technologies available through CBI. The new trade sale booth is being designed to be versatile enough to serve our diverse client base.



Human Resources



The Company currently has 52 full time employees including 5 employees in administration; 5 in marketing, sales, and/or customer relations; 1 computer network specialist;
and 41 employees in laboratory operations. 11 of the Companys employees hold doctorate degrees, and 7 have masters degrees. None of the Companys employees are represented by a labor union. The Company has experienced no work
stoppages and believes its relations with its employees to be good.



5



---

Competition



The Company faces several types of competition, but the Company believes that there are fewer than 5 companies which can be considered direct competitors across multiple
technologies. However, there are virtually no other companies which offer the breadth of CBIs services, especially with regard to its expertise in bio-defense related work.



Government Regulation



The Company does not require government regulatory approvals to provide its current services. Numerous federal, state and local agencies, such as environmental, working
condition and other similar regulators, have jurisdiction to take action that could have a material adverse effect upon the Companys ability to do business. The Company believes that it is in general compliance with existing federal, state and
local laws and regulations and does not anticipate that continuing compliance will have any material effect upon the capital expenditures, earnings or competitive position of the Company.



The Company anticipates that its pursuit of its growth strategy will subject the Company to a heightened level of government regulation of
its operations. For example, in pursuing opportunities to provide analytical services to customers seeking the approval of the United States Food and Drug Administration FDA of products, the Companys operations will become subject
to compliance with standards established by the FDA, including inspections by the FDA and other federal, state and local agencies regarding work performed by the Company on specific FDA submission projects. If significant violations are discovered
during an inspection, the Company may be restricted from undertaking additional work on projects until the violations are remedied. The Company has a license from the Nuclear Regulatory Commission NRC for conduct of work involving
radio-nuclides and operates a BSL3 facility under accreditation from the Centers for Disease Control.



|Item 2. | Description of Property.
|------- | ------------------------



Facilities



Construction of the Companys present facility was completed in November 1998 at an overall cost of approximately $ 5.1 million financed primarily through the Virginia Small Business Financing Authority
VSBFA that issued $ 4,000,000 in tax-exempt industrial revenue bonds IRBs for the benefit of the Company. On November 17 2004, the Company redeemed the IRBs for a conventional note payable to a bank. The note matures in
November 2009, with monthly payments of $25,347 of principal and interest at 5.25%.



The Companys facility, located in Richmond, VA, encompasses 32,000 square feet of state-of-the-art laboratory and administrative space. The building is designed to facilitate movement of samples throughout each laboratory, and where
necessary, to maintain and ensure custody of samples. The building houses expansion space, which was purposefully left undeveloped to accommodate new technologies as they come on board. The Company took possession of its current facility in late
November 1998, and all labs were fully operational in the facility by mid December 1998. The Company believes that the facility is adequately insured.



|Item 3. | Legal Proceedings.
|------- | ------------------



The Company is not subject to any pending legal proceeding required to be disclosed.



6



---

|Item 4. | Submission of Matters to a Vote of Security Holders.
|------- | ----------------------------------------------------



No matter was submitted to a vote of security holders in the fourth fiscal quarter of 2004.



PART II



|Item 5. | Market for Common Equity and Related Stockholder Matters.
|------- | ---------------------------------------------------------



The information set forth on page 5 the Companys 2004 Annual Report to Shareholders under the caption Market for Common Equity is incorporated herein by
reference.



The following table provides information about our equity
compensation plans as of December 31, 2004.



|                                                           |  |                                                                                            |  |                                                                             |      |                                                                                                                                         |        
|---------------------------------------------------------- |  | ------------------------------------------------------------------------------------------ |  | --------------------------------------------------------------------------- | ---- | --------------------------------------------------------------------------------------------------------------------------------------- | -------
|                                                           |  | a Number of securities tobe issued upon exerciseof outstanding options,warrants and rights |  | b Weighted-averageexercise price of outstandingoptions, warrants and rights |      | c Number of securitiesremaining available forfuture issuance underequity compensationplans (excludingsecurities reflected incolumn (a))
|Plan Category                                              |  |                                                                                            |  |                                                                             |      |                                                                                                                                         |        
|Equity compensation plans approved by security holders     |  | 855,153                                                                                    |  | $                                                                           | 6.34 |                                                                                                                                         | 184,847
|Equity compensation plans not approved by security holders |  | 0                                                                                          |  |                                                                             | 0    |                                                                                                                                         | 0      
|Total                                                      |  | 855,153                                                                                    |  | $                                                                           | 6.34 |                                                                                                                                         | 184,847



|Item 6. | Managements Discussion and Analysis or Plan of Operation.
|------- | ----------------------------------------------------------



The information set forth on pages 11 through 21 of the Companys 2004 Annual Report to Shareholders under the caption Managements Discussion and
Analysis of Financial Condition and Results of Operations is incorporated herein by reference.



|Item 7. | Financial Statements.
|------- | ---------------------



The Companys financial statements and the related notes thereto, together with the report of BDO Seidman LLP for 2004 and 2003, set forth on pages 23 through 39 of
the Companys 2004 Annual Report to Shareholders are incorporated herein by reference.



|Item 8. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
|------- | -------------------------------------------------------------------------------------



The Company is not presently involved in any disagreements with its independent auditors on accounting financial disclosures.



7



---

|Item 8A. | Controls and Procedures.
|-------- | ------------------------



The Company maintains a system of controls and procedures designed to provide reasonable assurance as to the reliability of the financial statements and other disclosures
included in this report, as well as to safeguard assets from unauthorized use or disposition. The Company evaluated the effectiveness of its disclosure controls and procedures (as defined in Rule 13a-14(c) and Rule 15a-14(c) under the Securities
Exchange Act of 1934) under the supervision and with the participation of management, including the Companys Chief Executive Officer and Controller, within 90 days prior to the filing date of this report. Based upon that evaluation, the
Companys Chief Executive Officer and Controller concluded that the Companys disclosure controls and procedures are effective in timely alerting them to information required to be included in the Companys periodic Securities and
Exchange Commission filings. There were no significant changes in the Companys internal controls or in other factor that could significantly affect these controls subsequent to the date of their evaluation.



|Item 8B | Other Information.
|------- | ------------------



The Company has previously reported all information required to be disclosed during the fourth quarter of 2004 in a report on Form 8-K.



PART III



|Item 9. | Directors, Executive Officers, Promoters and Control Persons;
|------- | -------------------------------------------------------------

Compliance with Section 16(a) of the Exchange Act.



Directors



The information relating to
the directors of the Company set forth in the Companys definitive proxy statement relating to the Companys Annual Meeting of Shareholders to be held on May 21, 2005 (the Proxy Statement) under the caption proposal one is
incorporated herein by reference.



Executive Officers



The information relating to the executive officers of the Company set forth in the Proxy
Statement under the caption Management-Business History of Executive Officers is incorporated herein by reference.



Compliance with Section 16(a) of the Securities Exchange Act of 1934



The information relating to compliance with Section 16(a) of the Securities Exchange Act of 1934, as amended, set forth in the Proxy Statement under the caption Section
16(a) Beneficial Ownership Reporting Compliance is incorporated herein by reference.



Code of Conduct



The information relating to the
Companys Code of Conduct is set forth in the Proxy Statement under the caption Code of Conduct is incorporated herein by reference.



|Item 10. | Executive Compensation.
|-------- | -----------------------



The information set forth in the Proxy Statement under the caption Executive Compensation is incorporated herein by reference.



8



---

|Item 11. | Security Ownership of Certain Beneficial Owners and Management.
|-------- | ---------------------------------------------------------------



The information set forth in the Proxy Statement under the caption Security ownership of Certain Beneficial owners and Management is incorporated herein by
reference.



|Item 12. | Certain Relationships and Related Transactions.
|-------- | -----------------------------------------------



Not applicable.



|Item 13. | Exhibits.
|-------- | ---------



| | (a) | Exhibits
| | --- | --------



|               |  |                                                                                                          
|-------------- |  | ---------------------------------------------------------------------------------------------------------
|Exhibit Number |  | Description of Exhibit                                                                                   
|               | 
|3.1            |  | Amended and Restated Articles of Incorporation (1)                                                       
|               | 
|3.2            |  | Second Amended and Restated Bylaws (6)                                                                   
|               | 
|4.1            |  | Form of Common Stock Certificate (1)                                                                     
|               | 
|10.1           |  | Placement Agreement by and between the Company and Anderson & Strudwick, Incorporated (A&S) (1)        
|               | 
|10.2           |  | Warrant Agreement between the Company and A&S (1)                                                        
|               | 
|10.3           |  | Warrant Agreement between the Company and Richard J. Freer, as amended (1)                               
|               | 
|10.4           |  | Warrant Agreement between the Company and Thomas R. Reynolds, as amended (1)                             
|               | 
|10.5           |  | Warrant Agreement between the Company and Robert B. Harris, as amended (1)                               
|               | 
|10.6           |  | Employment Agreement for Richard J. Freer (2)                                                            
|               | 
|10.7           |  | First Amended and Restated Employment Agreement for Thomas R. Reynolds (2)                               
|               | 
|10.8           |  | First Amended and Restated Employment Agreement for Robert B. Harris (3)                                 
|               | 
|10.9           |  | Executive Severance Agreement for Richard J. Freer (1)                                                   
|               | 
|10.10          |  | 1997 Stock Incentive Plan, as amended (1)                                                                
|               | 
|10.11          |  | 2000 Stock Incentive Plan (4)                                                                            
|               | 
|10.12          |  | 2002 Stock Incentive Plan (5)                                                                            
|               | 
|13.1           |  | Annual Report to Shareholders for the Fiscal Year Ended December 31, 2004 incorporated in Form 10-KSB (6)
|               | 
|23.1           |  | Letter of Consent from BDO Seidman LLP (6)                                                               
|               | 
|31.1           |  | Certification of Robert B. Harris, Ph.D. (6)                                                             
|               | 
|31.2           |  | Certification of James H. Brennan (6)                                                                    
|               | 
|32.1           |  | Section 906 Certification of Robert B. Harris, Ph.D. (6)                                                 
|               | 
|32.2           |  | Section 906 Certification of James H. Brennan (6)                                                        

---

|(1) | Incorporated by reference to the Companys Registration Statement on Form SB-2, Registration No. 333-31731.
|--- | -----------------------------------------------------------------------------------------------------------



|(2) | Incorporated by reference to the Companys Current Report on Form 8-K, dated February 10, 2005, File No. 001-13467.
|--- | -------------------------------------------------------------------------------------------------------------------



|(3) | Incorporated by reference to the Companys Current Report on Form 8-K dated February 8, 2005, File No. 001-13467.
|--- | -----------------------------------------------------------------------------------------------------------------



|(4) | Incorporated by reference to the Companys Registration Statement on Form S-8, Registration No. 333-51074.
|--- | ----------------------------------------------------------------------------------------------------------



9



---

|(5) | Incorporated by reference to the Companys Registration Statement on Form S-8, Registration No. 333-102368.
|--- | -----------------------------------------------------------------------------------------------------------



|(6) | Filed herewith.
|--- | ---------------



Executive Compensation Plans and Arrangements



The following is a list of all executive compensation plans and arrangements filed as exhibits to this annual report on Form 10-KSB or incorporated herein by reference:



| | 1. | Warrant Agreement between the Company and Richard J. Freer, as amended (1)
| | -- | --------------------------------------------------------------------------



| | 2. | Warrant Agreement between the Company and Thomas R. Reynolds, as amended (1)
| | -- | ----------------------------------------------------------------------------



| | 3. | Warrant Agreement between the Company and Robert B. Harris, as amended (1)
| | -- | --------------------------------------------------------------------------



| | 4. | Employment Agreement between the Company and Richard J. Freer (1)
| | -- | -----------------------------------------------------------------



| | 5. | First Amended and Restated Employment Agreement between the Company and Thomas R. Reynolds (2)
| | -- | ----------------------------------------------------------------------------------------------



| | 6. | First Amended and Restated Employment Agreement between the Company and Robert B. Harris (3)
| | -- | --------------------------------------------------------------------------------------------



| | 7. | Executive Severance Agreement between the Company and Richard J. Freer (1)
| | -- | --------------------------------------------------------------------------



| | 8. | 1997 Stock Incentive Plan (1)
| | -- | -----------------------------



| | 9. | 2000 Stock Incentive Plan (4)
| | -- | -----------------------------



| | 10. | 2002 Stock Incentive Plan (5)
| | --- | -----------------------------

---

|(1) | Previously filed as an exhibit to the Companys Registration Statement on Form SB-2, Registration No. 333-31731, and incorporated by reference herein.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------



|(2) | Incorporated by reference to the Companys Current Report on Form 8-K dated February 10, 2005, File No. 001-13467.
|--- | ------------------------------------------------------------------------------------------------------------------



|(3) | Incorporated by reference to the Companys Current Report on Form 8-K dated February 8, 2005 File No. 001-13467
|--- | ---------------------------------------------------------------------------------------------------------------



|(4) | Previously filed as an exhibit to the Companys Registration Statement on Form S-8, Registration No. 333-116583, and incorporated by reference herein.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------



|(5) | Previously filed as an exhibit to the Companys Registration Statement on Form S-8, Registration No. 333-102368, and incorporated by reference herein.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------



|Item 14. | Principal Accountant Fees and Services.
|-------- | ---------------------------------------



The information set forth in the Proxy Statement under the caption Appointment of Independent Registered Public Accountants is incorporated herein by
reference.



10



---



SIGNATURES



In accordance with Section 13 or 15(d) of the Securities Exchange Act of
1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



|                     |  |  |  |                                    |  |                             |  |                       
|-------------------- |  |  |  | ---------------------------------- |  | --------------------------- |  | ----------------------
|                     |  |  |  | COMMONWEALTH BIOTECHNOLOGIES, INC.
|                     |  |  | 
|Date: March 30, 2005 |  |  |  | By:                                |  | /s/ Robert B. Harris, Ph.D.
|                     |  |  |  |                                    |  |                             |  | Robert B. Harris, Ph.D
|                     |  |  |  |                                    |  |                             |  | President             



In accordance with the Exchange Act,
this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.



|                                                   |  |                                                          |  |               
|-------------------------------------------------- |  | -------------------------------------------------------- |  | --------------
|Name                                               |  | Title(s)                                                 |  | Date          
|                                                   |  |                                                         
|/s/ Richard J. Freer, Ph.D.Richard J. Freer, Ph.D. |  | Chairman, COO and Director (Principal Executive
Officer) |  | March 30, 2005
|                                                   |  |                                                         
|/s/ Robert B. Harris, Ph.D.Robert B. Harris, Ph.D. |  | President, CEO and Director                              |  | March 30, 2005
|                                                   |  |                                                         
|/s/ Thomas R. ReynoldsThomas R. Reynolds           |  | Executive Vice President, Secretary and
Director         |  | March 30, 2005
|                                                   |  |                                                         
|/s/ James H. BrennanJames H. Brennan               |  | Controller (Principal Financial and Accounting
Officer)  |  | March 30, 2005
|                                                   |  |                                                         
|/s/ James P. CauseyJames P. Causey                 |  | Director                                                 |  | March 30, 2005
|                                                   |  |                                                         
|/s/ Samuel P. Sears, Jr.Samuel P. Sears, Jr.       |  | Director                                                 |  | March 30, 2005
|                                                   |  |                                                         
|/s/ Gerald P. Krueger PhD.Gerald P. Krueger PhD.   |  | Director                                                 |  | March 30, 2005
|                                                   |  |                                                         
|/s/ Dr. Donald McAfeeDr. Donald McAfee             |  | Director                                                 |  | March 30, 2005
|                                                   |  |                                                         
|/s/ Peter C. EinselenPeter C. Einselen             |  | Director                                                 |  | March 30, 2005



11